Skip to main content

Increasing AWAREness of CKD and T2D

This short video narrated by Dr Abitbol features highlights from AWARE-CKD1 - a Canadian study assessing awareness, values, and preferences of physicians and patients with respect to CKD and T2D management.

Diabetes remains the leading contributor to the development of chronic kidney disease (CKD) and end-stage kidney disease, emphasizing the urgency of identifying barriers to early diagnosis and intervention. The primary objective of this study was to describe the awareness, values and preferences of physicians and patients with respect to managing CKD among patients with type 2 diabetes (T2D).

1. Chu L, Bhogal SK, Lin P, et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022; 46:464-472. Link to article

Dr. Alexander Abitbol joined LMC in 2015 after relocating to Toronto. He graduated medical school at McGill University in Montreal, Quebec in 2010. He completed residency at McGill in Internal Medicine and sub-specialized in Endocrinology and Metabolism, where he served as chief resident and won awards at every level of education and training. He received certifications in Internal Medicine by the Royal College of Physicians and Surgeons of Canada and the American Board of Internal Medicine.